Nanostring GeoMx Annual Service Contract
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Place of performance: Bethesda, MD
Free. Verify your email, then we send one reminder only.
- Posted
- Jun 23, 2026
- Closes
- Rolling, no fixed deadline
Similar opportunities open now
- high-throughput proteomics platform that uses proximity extension and LicenseOpenDEPT OF DEFENSENo deadline listed
- Dovetail Genomics LLC Micro-C ServiceSame funderOpenHEALTH AND HUMAN SERVICES, DEPARTMENT OFNo deadline listed
- Multiomic profiling of cardiometabolic diseases (Illumina)Same funderOpenHEALTH AND HUMAN SERVICES, DEPARTMENT OFNo deadline listed
- Software for a NanoTest Xtreme instrumentOpenCOMMERCE, DEPARTMENT OFNo deadline listed
- TECHNOLOGY LICENSING OPPORTUNITY: Multidimensional Mass Fingerprinting for Antibiotic-Resistant Bacteria (MultiScan-AR)OpenENERGY, DEPARTMENT OFNo deadline listed
At a glance
This is a government contract opportunity posted by HEALTH AND HUMAN SERVICES, DEPARTMENT OF in the analytical laboratory instrument manufacturing category. Applications are accepted on a rolling basis. Work is performed in Bethesda, MD.
Classification and identifiers
- Industry (NAICS)
- Analytical Laboratory Instrument Manufacturing (334516)
- Product or service (PSC)
- Maintenance, Repair and Rebuilding of Equipment: Instruments and Laboratory Equipment (J066)
- Solicitation number
- 75N98026Q00674
- Contracting office
- NATIONAL INSTITUTES OF HEALTH OLAO
Who can apply
No Set aside used. NONE
About this opportunity
We purchased the GeoMx Digital Spatial Profiler (DSP) instrument to study tissue heterogeneity and the complexity of microenvironments in the spatial context related to alcohol-induced organ injury and in various fibrosis models. GeoMx DSP is the only spatial biology platform that non-destructively profiles the expression of RNA and protein from distinct tissue compartments and cell populations with an automated and scalable workflow that integrates with standard histology staining. This technique will help us discover novel biomarkers for disease severity, understand disease mechanisms and progression, uncover drug mechanisms of action, and study preclinical models. Currently, multiple labs at NIAAA plan to use this instrument for their ongoing projects.